National Healthcare Administration: Setting a Certain Price Stabilization Period for High-Level Innovative Drugs
Gloomy Times, July 31st | Wang Xiaoning, Director of the Pharmaceutical Pricing and Procurement Department of the National Healthcare Administration, stated that we support high-level innovative dru